U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=24068167; http://www.ncbi.nlm.nih.gov/pubmed/23729002

Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. GLP-2 is known to increase intestinal and portal blood flow, and inhibit gastric acid secretion. Teduglutide binds to the glucagon-like peptide-2 receptors located in intestinal subpopulations of enteroendocrine cells, subepithelial myofibroblasts and enteric neurons of the submucosal and myenteric plexus. Activation of these receptors results in the local release of multiple mediators including insulin-like growth factor (IGF)-1, nitric oxide and keratinocyte growth factor (KGF). FDA approved on December 21, 2012. In Europe it has been granted orphan drug status and is marketed under the brand Revestive by Nycomed. It works by promoting mucosal growth and possibly restoring gastric emptying and secretion.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: Samples of cerebrospinal fluid (CSF) and plasma were collected from rats administered teduglutide s.c. at a single dose of 3 or 10 mg/kg. The CSF teduglutide concentration did not exceed 5% of the peak concentrations in plasma. The results indicated that teduglutide did not readily penetrate the blood-brain barrier.

Originator

Approval Year

2012
595
Targets

Targets

Primary TargetPharmacologyConditionPotency
Glucagon-like peptide 2 receptor
1
Target ID: O95838
Gene ID: 9340.0
Gene Symbol: GLP2R
Target Organism: Homo sapiens (Human)
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
GATTEX KIT

Approved Use

GATTEX® (teduglutide [rDNA origin]) for injection is a glucagon-like peptide-2 (GLP-2) analog indicated for the treatment of adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support

Launch Date

1.35604797E12
PubMed

PubMed

TitleDatePubMed
The long road to a new short-bowel therapy: teduglutide for clinical use.
2013 Jul
Teduglutide: a review of its use in the treatment of patients with short bowel syndrome.
2013 Jun
Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study.
2013 Nov-Dec
Patents

Patents

CN104045707A
1
CN104072603A
1
WO2015077154A1
1

Sample Use Guides

In Vivo Use Guide
The recommended once daily dose of GATTEX (teduglutide [rDNA origin]) is 0.05 mg/kg. Administer by subcutaneous injection; alternate sites between 1 of the 4 adjusted, and GATTEX treatment reassessed quadrants of the abdomen, or into alternating thighs or alternating arms.
Route of Administration: Other
In Vitro Use Guide
Proliferation was assessed using a colorimetric MTS assay after Caco-2 cells were incubated with 0 to 1000 nM teduglutide.
Name Type Language
TEDUGLUTIDE
DASH   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
ALX 0600 (2-GLYCINE-1-33-GLUCAGON-LIKE PEPTIDE II (HUMAN))
Common Name English
TEDUGLUTIDE [USAN]
Common Name English
TEDUGLUTIDE [MI]
Common Name English
2-GLYCINE-1-33-GLUCAGON-LIKE PEPTIDE II (HUMAN)
Common Name English
ALX-0600
Code English
TEDUGLUTIDE [JAN]
Common Name English
TEDUGLUTIDE (RDNA ORIGIN)
Common Name English
ALX 0600
Code English
TEDUGLUTIDE RECOMBINANT [ORANGE BOOK]
Common Name English
Teduglutide [WHO-DD]
Common Name English
GATTEX
Brand Name English
TEDUGLUTIDE [MART.]
Common Name English
teduglutide [INN]
Common Name English
REVESTIVE
Brand Name English
TEDUGLUTIDE RECOMBINANT
ORANGE BOOK  
Common Name English
TEDUGLUTIDE [VANDF]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/01/077
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
WHO-ATC A16AX08
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
FDA ORPHAN DRUG 784820
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
NDF-RT N0000190992
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
EMA ASSESSMENT REPORTS REVESTIVE (AUTHORIZED: MALABSORPTION DISEASES)
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
FDA ORPHAN DRUG 126999
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
NCI_THESAURUS C548
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
WHO-VATC QA16AX08
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
Code System Code Type Description
DRUG CENTRAL
4718
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
MERCK INDEX
m10518
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL2104987
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
DRUG BANK
DB08900
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
NCI_THESAURUS
C66582
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
NDF-RT
N0000175140
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY Glucagon-Like Peptide 2 [Chemical/Ingredient]
SMS_ID
100000124173
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
MESH
C494910
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
CHEBI
72305
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
RXCUI
1364468
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY RxNorm
DAILYMED
7M19191IKG
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
WIKIPEDIA
TEDUGLUTIDE
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
NDF-RT
N0000190990
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY Glucagon-like Peptide-2 (GLP-2) Agonists [MoA]
HSDB
8337
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
CAS
197922-42-2
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
NDF-RT
N0000175452
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY Analogs/Derivatives [Chemical/Ingredient]
FDA UNII
7M19191IKG
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
USAN
PP-09
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
EVMPD
SUB31909
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
INN
8444
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
IUPHAR
7049
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
EPA CompTox
DTXSID501027767
Created by admin on Sat Dec 16 00:01:42 UTC 2023 , Edited by admin on Sat Dec 16 00:01:42 UTC 2023
PRIMARY
ACTIVE MOIETY
TEDUGLUTIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966